MX2017011169A - Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro. - Google Patents

Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro.

Info

Publication number
MX2017011169A
MX2017011169A MX2017011169A MX2017011169A MX2017011169A MX 2017011169 A MX2017011169 A MX 2017011169A MX 2017011169 A MX2017011169 A MX 2017011169A MX 2017011169 A MX2017011169 A MX 2017011169A MX 2017011169 A MX2017011169 A MX 2017011169A
Authority
MX
Mexico
Prior art keywords
iron
deficiency anemia
patients
ferric citrate
colitis
Prior art date
Application number
MX2017011169A
Other languages
English (en)
Spanish (es)
Inventor
Poradosu Enrique
Bentsur Ron
David SHEMESH Shay
Original Assignee
Keryx Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keryx Biopharmaceuticals Inc filed Critical Keryx Biopharmaceuticals Inc
Publication of MX2017011169A publication Critical patent/MX2017011169A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02—Iron compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2017011169A 2015-03-04 2016-03-03 Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro. MX2017011169A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562127963P 2015-03-04 2015-03-04
PCT/US2016/020575 WO2016141124A1 (en) 2015-03-04 2016-03-03 Use of ferric citrate in the treatment of iron-deficiency anemia

Publications (1)

Publication Number Publication Date
MX2017011169A true MX2017011169A (es) 2017-11-09

Family

ID=56848619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011169A MX2017011169A (es) 2015-03-04 2016-03-03 Uso de citrato ferrico en el tratamiento de anemia por deficiencia de hierro.

Country Status (15)

Country Link
US (2) US20180071243A1 (enExample)
EP (1) EP3265077A4 (enExample)
JP (2) JP2018507260A (enExample)
KR (1) KR20170123664A (enExample)
CN (1) CN107530310A (enExample)
AU (1) AU2016226250B2 (enExample)
BR (1) BR112017018963A2 (enExample)
CA (1) CA2978073A1 (enExample)
EA (1) EA201791960A1 (enExample)
HK (2) HK1248589A1 (enExample)
IL (1) IL254125A0 (enExample)
MX (1) MX2017011169A (enExample)
SG (1) SG11201707120PA (enExample)
TW (2) TW202302083A (enExample)
WO (1) WO2016141124A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120046753A (ko) 2009-07-21 2012-05-10 케릭스 바이오파마슈티컬스 인코포레이티드 구연산철 투여형태
US20210085711A1 (en) * 2017-09-19 2021-03-25 Japan Tobacco Inc. Use of ferric citrate in prevention and/or treatment of iron-deficiency anemia in hypermenorrhea patient and/or patient suffering from hypermenorrhea-associated gynecologic disease
FR3075601A1 (fr) * 2017-12-21 2019-06-28 Clarisse Le Court Complements alimentaires et leur utilisation sur les menstruations
US12467933B2 (en) 2019-06-07 2025-11-11 Arizona Board Of Regents On Behalf Of Arizona State University Body fluid iron level panel analyzer
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
WO2023047424A1 (en) * 2022-04-29 2023-03-30 West Bengal Chemical Industries Limited Pharmaceutical acceptable iron (iii) coordination complex having high phosphate binding capacity and preparation thereof
KR102623739B1 (ko) * 2022-07-28 2024-01-11 주식회사 페라메드 시트르산과 철을 포함하는 착화합물 및 그를 포함하는 식품 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI335218B (en) * 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
US8093423B2 (en) * 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
JP4931352B2 (ja) * 2004-01-14 2012-05-16 月桂冠株式会社 鉄補給剤及びその利用
CA2552889A1 (en) * 2004-01-14 2005-07-28 Sachiko Suzuki Iron supplement and utilization of the same
NZ566743A (en) * 2005-08-18 2010-07-30 Globoasia Llc Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same
WO2012097155A1 (en) * 2011-01-14 2012-07-19 Chiasma Inc. Improved pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof
SG11201408521WA (en) * 2012-06-21 2015-01-29 Keryx Biopharmaceuticals Inc Use of ferric citrate in the treatment of chronic kidney disease patients

Also Published As

Publication number Publication date
HK1246649A1 (zh) 2018-09-14
TW202302083A (zh) 2023-01-16
JP2018507260A (ja) 2018-03-15
KR20170123664A (ko) 2017-11-08
WO2016141124A1 (en) 2016-09-09
CN107530310A (zh) 2018-01-02
BR112017018963A2 (pt) 2018-05-15
EP3265077A1 (en) 2018-01-10
HK1248589A1 (zh) 2018-10-19
EP3265077A4 (en) 2018-10-24
TW201639558A (zh) 2016-11-16
TWI812580B (zh) 2023-08-21
EA201791960A1 (ru) 2018-01-31
US20240075006A1 (en) 2024-03-07
SG11201707120PA (en) 2017-09-28
CA2978073A1 (en) 2016-09-09
JP2021091686A (ja) 2021-06-17
AU2016226250A1 (en) 2017-09-28
IL254125A0 (en) 2017-10-31
US20180071243A1 (en) 2018-03-15
AU2016226250B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
HK1246649A1 (zh) 柠檬酸铁在治疗缺铁性贫血中的用途
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MY189333A (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
PH12017501420A1 (en) Compositions and methods of tumor treatment utilizing nanoparticles
JO3709B1 (ar) تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
PH12018500762A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
WO2015148389A3 (en) Diagnosis of multiple sclerosis in human and animal subjects
MX2017017136A (es) Composicion para el tratamiento de la nafld.
MX2019013683A (es) Una combinacion farmaceutica para el tratamiento de un cancer.
EA201891922A1 (ru) Лекарственное средство для лечения инфекций на фоне диабетической стопы
Habibian Comparision of therapeutic effect of osveral & desferal in patients with thalassemia (Bahonar Hospital in Karaj 2012-2013)
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
이은석 et al. Effects of Exercise Programs on Cancer Patients: a Systematic Literature Review a Systematic Literature Review
Au Subcutaneous nodular sarcoidosis: case report
Demchuk et al. TREATMENT OF PATIENTS WITH CHRONIC DISEASE KIDNEYS OF THE PRESENCE OF LESIONS GASTRODUODENAL AREAS AND CHRONIC PYLONEPHRITIS IN COMBINATION WITH METABOLIC SYNDROME
RU2012158011A (ru) Метод и композиция для лечения рака
Jong Curative effect of Beifushu and Aikexin in treating residual burn wounds
Saito Skin rash: case report